PROLONGED ACTION PHARMACEUTICAL COMPOSITION BASED ON 5-ETHOXY-2-[2-(MORPHOLINO)-ETHYLTHIO]BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE (APHOBAZOLUM) Russian patent published in 2019 - IPC A61K31/415 A61K9/22 A61K47/38 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to a pharmaceutical composition having anxiolytic action and containing as a medicinal agent a therapeutically effective amount of Aphobazolum - 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride and/or base, and as additional pharmaceutically acceptable components, which impart novel consumer properties to the drug on the basis of the declared composition: a combination of release modifiers, specifically, a release retarder and a hydrophilic release modifier, with a certain quantitative ratio thereof, as well as a group of substances providing a sufficient mass of the dosage form, binding substances, sliding/lubricating substances, and film casing. Aphobazolum-based dosage forms can be presented both in the form of tablets, capsules, granules, powder, providing duration of action of the drug for at least 8 hours.

EFFECT: implementation of the invention enables to obtain a pharmaceutical composition exhibiting prolonged release of the active pharmaceutical ingredient, which enables to stabilize the concentration of the preparation in the human body for a day and thereby reduce the frequency of taking the preparation for a day to achieve the desired therapeutic effect.

6 cl, 14 tbl, 2 dwg